XOMA (XOMA) Given a $49.00 Price Target by HC Wainwright Analysts

HC Wainwright set a $49.00 price objective on XOMA (NASDAQ:XOMA) in a report published on Friday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.

Several other analysts have also commented on the stock. ValuEngine raised shares of XOMA from a sell rating to a hold rating in a research report on Friday. Zacks Investment Research lowered shares of XOMA from a buy rating to a hold rating in a research report on Wednesday, February 21st. Wedbush reissued a buy rating and set a $33.00 price target on shares of XOMA in a research report on Tuesday, December 19th. Finally, TheStreet raised shares of XOMA from an e+ rating to a c- rating in a research report on Wednesday, November 29th. One research analyst has rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus target price of $38.33.

How to Become a New Pot Stock Millionaire

Shares of XOMA (NASDAQ:XOMA) opened at $23.19 on Friday. The company has a market cap of $193.15, a PE ratio of 31.77 and a beta of 3.03. XOMA has a 1 year low of $5.27 and a 1 year high of $37.25. The company has a current ratio of 5.96, a quick ratio of 3.45 and a debt-to-equity ratio of 2.52.

XOMA (NASDAQ:XOMA) last released its quarterly earnings results on Wednesday, March 7th. The biotechnology company reported ($0.16) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.35) by $0.19. The business had revenue of $5.36 million during the quarter, compared to analyst estimates of $4.12 million. XOMA had a net margin of 27.49% and a negative return on equity of 130.44%. equities research analysts predict that XOMA will post -0.62 EPS for the current year.

Hedge funds have recently added to or reduced their stakes in the business. Millennium Management LLC raised its position in shares of XOMA by 1,404.7% in the 4th quarter. Millennium Management LLC now owns 196,759 shares of the biotechnology company’s stock valued at $7,005,000 after purchasing an additional 183,683 shares during the last quarter. Bogle Investment Management L P DE purchased a new position in shares of XOMA in the 4th quarter valued at approximately $3,657,000. Two Sigma Investments LP raised its position in shares of XOMA by 717.5% in the 4th quarter. Two Sigma Investments LP now owns 88,692 shares of the biotechnology company’s stock valued at $3,157,000 after purchasing an additional 77,843 shares during the last quarter. EAM Investors LLC purchased a new position in shares of XOMA in the 3rd quarter valued at approximately $835,000. Finally, AXA purchased a new position in shares of XOMA in the 4th quarter valued at approximately $1,211,000. 39.76% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “XOMA (XOMA) Given a $49.00 Price Target by HC Wainwright Analysts” was first published by Markets Daily and is the property of of Markets Daily. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at https://www.themarketsdaily.com/2018/03/12/xoma-xoma-given-a-49-00-price-target-by-hc-wainwright-analysts.html.

XOMA Company Profile

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply